Welcome to our dedicated page for Averin Cap Acquisition SEC filings (Ticker: ACAAU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Averin Cap Acquisition's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Averin Cap Acquisition's regulatory disclosures and financial reporting.
Averin Capital Acquisition Corp., a blank check company listed on Nasdaq, announced that holders of its IPO units can begin separately trading the underlying securities on April 10, 2026. Each unit consists of one Class A ordinary share with a par value of $0.0001 and one-sixth of a redeemable warrant.
The Class A ordinary shares will trade under the symbol ACAA and the whole warrants under ACAAW, while any units that remain bundled will continue to trade as ACAAU. Each whole warrant allows the purchase of one Class A ordinary share at an exercise price of $11.50 per share.
Averin Capital Acquisition Corp., a Cayman Islands-based special purpose acquisition company, completed a partial exercise of the underwriters’ over-allotment option tied to its recent IPO. The underwriters purchased an additional 3,386,008 units at $10.00 per unit, adding $33,860,080 in gross proceeds.
The IPO originally sold 25,000,000 units at $10.00 per unit, and a concurrent private placement of 200,000 units to the sponsor added $2,000,000. In total, 28,386,008 public units and 200,000 private placement units have been sold for aggregate gross proceeds of $283,860,080, all largely held in a U.S. trust account. Each unit includes one Class A ordinary share and one-sixth of a redeemable warrant exercisable at $11.50 per share.
Averin Capital Acquisition Corp. shows that Sculptor-affiliated entities beneficially own 1,500,000 Class A ordinary shares, representing 5.95% of the class.
The filing states the ownership reflects shared voting and dispositive power for 1,500,000 shares across Sculptor Capital, Sculptor Capital II and related entities, calculated using 25,200,000 shares outstanding as set forth in the issuer's Form 8-K dated 02/26/2026.
Averin Capital Acquisition Sponsor LLC and related parties report beneficial ownership of 7,387,500 ordinary shares, or 20.44%, of Averin Capital Acquisition Corp. This stake consists of 200,000 Class A Ordinary Shares and 7,187,500 Class B Ordinary Shares, with 937,500 Class B shares subject to possible forfeiture.
The Class B shares are automatically convertible into Class A shares on a one-for-one basis at the initial business combination or earlier at the holder’s option. Amendment No. 1 adds Eric Berry as an additional reporting person alongside the Sponsor, Handel Rose LLC, and David Berry, who together share voting and investment discretion over the Sponsor’s holdings.
All three—Handel Rose LLC, David Berry, and Eric Berry—may be deemed to beneficially own the Sponsor’s securities but each disclaims beneficial ownership beyond any direct or indirect interests. The filing notes no transactions in the issuer’s ordinary shares by the reporting persons during the 60 days preceding the report.
Averin Capital Acquisition Sponsor LLC reported buying 200,000 Class A ordinary shares of Averin Capital Acquisition Corp. at $10.00 per share on 2025-02-20, bringing its reported Class A holdings to 200,000 shares.
The shares represent stock underlying private placement units, each unit including one Class A share and one-sixth of a warrant exercisable for an additional Class A share. The Sponsor holds these shares of record, while Handel Rose LLC controls the Sponsor. Eric Berry and David Berry may be deemed beneficial owners through Handel Rose LLC but each disclaims beneficial ownership beyond any pecuniary interest. A separate 7,187,500 Class B ordinary shares is noted, which will convert into Class A shares in connection with the company’s initial business combination or earlier at the holder’s option.
Averin Capital Acquisition Corp. reported initial insider holdings of 7,387,500 Class B ordinary shares through Averin Capital Acquisition Sponsor LLC. These Class B shares automatically convert into Class A ordinary shares on a one-for-one basis at the company’s initial business combination or earlier at the holder’s option, subject to adjustments.
The Class B shares have no expiration date and include up to 937,500 shares subject to forfeiture if the underwriters of the initial public offering do not fully exercise their over-allotment option. Handel Rose LLC controls the sponsor, and Eric Berry and David Berry may be deemed beneficial owners but disclaim ownership beyond any pecuniary interest.
Averin Capital Acquisition Sponsor LLC, together with David Berry and Handel Rose LLC, reports beneficial ownership of 7,387,500 ordinary shares of Averin Capital Acquisition Corp., representing 20.44% of 36,137,500 Class A and Class B shares outstanding as of February 20, 2026.
The position includes 200,000 Class A shares in private placement units and 7,187,500 Class B founder shares, which are automatically convertible into Class A shares on a one-for-one basis. The Sponsor paid an aggregate $2,025,000 using its working capital.
The Sponsor and David Berry agreed in an insider letter to vote their founder shares, placement shares and certain public shares in favor of any proposed business combination and not to redeem these shares, and accepted lock-up, indemnification and registration rights obligations tied to the SPAC’s IPO structure and trust account protections.
Averin Capital Acquisition Corp. completed its initial public offering of 25,000,000 units at $10.00 per unit, raising gross proceeds of $250,000,000. Each unit includes one Class A ordinary share and one-sixth of a redeemable warrant exercisable at $11.50 per share.
The company also sold 200,000 private placement units to its sponsor for $2,000,000, and a total of $250,000,000 was deposited into a U.S. trust account. An additional 3,750,000 units may be sold under an over-allotment option. Public shareholders will have redemption rights in connection with a future business combination.
The independent auditor issued an unqualified opinion on the balance sheet as of February 20, 2026, but highlighted that ongoing costs and the need to complete a business combination raise substantial doubt about Averin Capital’s ability to continue as a going concern.
Averin Capital Acquisition Sponsor LLC, an affiliate of Averin Capital Acquisition Corp., bought 200,000 Class A ordinary shares at $10.0000 per share on February 20, 2025. After this open-market purchase, the sponsor directly holds 200,000 Class A ordinary shares.
The shares represent stock underlying private placement units acquired under a Private Placement Units Purchase Agreement between the sponsor and Averin Capital Acquisition Corp.. Handel Rose LLC is the sole managing member of the sponsor and controls voting and investment decisions. Eric Berry and David Berry, as managers of Handel Rose LLC, may be deemed beneficial owners but each disclaims beneficial ownership beyond any pecuniary interest.
Averin Capital Acquisition Corp., a Cayman Islands blank check company, completed its initial public offering of 25,000,000 units at $10.00 per unit, generating gross proceeds of $250,000,000. Each unit includes one Class A ordinary share and one-sixth of one redeemable warrant exercisable at $11.50 per share, and the underwriter has a 45-day option to buy up to 3,750,000 additional units.
The company also sold 200,000 private placement units to its sponsor at $10.00 per unit, and a total of $250,000,000 from the IPO and private placement was placed in a U.S.-based trust account. These funds will remain in trust until a business combination is completed or public shares are redeemed under the company’s 24‑month deadline and related charter provisions. The board added three directors, formed audit and compensation committees, adopted amended and restated governing documents, and executed key agreements typical for a newly public blank check company focusing on technology and health industry targets.